<SEC-DOCUMENT>0000080255-25-000800.txt : 20251114
<SEC-HEADER>0000080255-25-000800.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114121923
ACCESSION NUMBER:		0000080255-25-000800
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-37761
		FILM NUMBER:		251483432

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRICE T ROWE ASSOCIATES INC /MD/
		CENTRAL INDEX KEY:			0000080255
		STANDARD INDUSTRIAL CLASSIFICATION:	SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200]
		ORGANIZATION NAME:           	09 Crypto Assets
		EIN:				520556948
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1307 POINT STREET
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21231
		BUSINESS PHONE:		(410)345-2000

	MAIL ADDRESS:	
		STREET 1:		P.O. BOX 89000
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21289
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:ns2="http://www.sec.gov/edgar/common">
    <headerData>
        <submissionType>SCHEDULE 13G/A</submissionType>
        <previousAccessionNumber>0000080255-25-000177</previousAccessionNumber>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0000080255</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>


        </filerInfo>
    </headerData>
    <formData>
        <coverPageHeader>
            <amendmentNo>1</amendmentNo>
            <securitiesClassTitle>COMMON STOCK</securitiesClassTitle>
            <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
            <issuerInfo>
                <issuerCik>0000744218</issuerCik>
                <issuerName>CELLDEX THERAPEUTICS INC</issuerName>
                <issuerCusip>15117B202</issuerCusip>
                <issuerPrincipalExecutiveOfficeAddress>
                    <ns2:street1>53 FRONTAGE ROAD</ns2:street1>
                    <ns2:street2>SUITE 220</ns2:street2>
                    <ns2:city>HAMPTON</ns2:city>
                    <ns2:stateOrCountry>NJ</ns2:stateOrCountry>
                    <ns2:zipCode>08827</ns2:zipCode>
                </issuerPrincipalExecutiveOfficeAddress>
            </issuerInfo>
            <designateRulesPursuantThisScheduleFiled>
                <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
            </designateRulesPursuantThisScheduleFiled>
        </coverPageHeader>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>T. Rowe Price Associates, Inc.</reportingPersonName>
            <citizenshipOrOrganization>MD</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>2342174</soleVotingPower>
                <sharedVotingPower>0</sharedVotingPower>
                <soleDispositivePower>2382518</soleDispositivePower>
                <sharedDispositivePower>0</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2382701</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
            <classPercent>3.6</classPercent>
            <typeOfReportingPerson>IA</typeOfReportingPerson>
        </coverPageHeaderReportingPersonDetails>
        <items>
            <item1>
                <issuerName>CELLDEX THERAPEUTICS INC</issuerName>
                <issuerPrincipalExecutiveOfficeAddress>53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827</issuerPrincipalExecutiveOfficeAddress>
            </item1>
            <item2>
                <filingPersonName>T. Rowe Price Associates, Inc.</filingPersonName>
                <principalBusinessOfficeOrResidenceAddress>1307 Point Street, Baltimore, MD 21231</principalBusinessOfficeOrResidenceAddress>
                <citizenship>Maryland</citizenship>
            </item2>
            <item3>
                <notApplicableFlag>N</notApplicableFlag>
                <typeOfPersonFiling>IA</typeOfPersonFiling>
            </item3>
            <item4>
                <amountBeneficiallyOwned>2382701</amountBeneficiallyOwned>
                <classPercent>3.6</classPercent>
                <numberOfSharesPersonHas>
                    <solePowerOrDirectToVote>2342174</solePowerOrDirectToVote>
                    <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
                    <solePowerOrDirectToDispose>2382518</solePowerOrDirectToDispose>
                    <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
                </numberOfSharesPersonHas>
            </item4>
            <item5>
                <notApplicableFlag>N</notApplicableFlag>
                <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
            </item5>
            <item6>
                <notApplicableFlag>Y</notApplicableFlag>
            </item6>
            <item7>
                <notApplicableFlag>Y</notApplicableFlag>
            </item7>
            <item8>
                <notApplicableFlag>Y</notApplicableFlag>
            </item8>
            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
            </item9>
            <item10>
                <notApplicableFlag>N</notApplicableFlag>
                <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.</certifications>
            </item10>
        </items>
        <signatureInformation>
            <reportingPersonName>T. Rowe Price Associates, Inc.</reportingPersonName>
            <signatureDetails>
                <signature>Ellen York</signature>
                <title>Vice President</title>
                <date>11/14/2025</date>
            </signatureDetails>
        </signatureInformation>
    </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
